Neural Tube Defects
1
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
BayerLEVERKUSEN, Germany
1 program1
Drospirenone/Ethinylestradiol/MethyltetrahydrofolatePhase 31 trial
Active Trials
Oregon TherapeuticsFrance - Paris
1 programFetoscopic Neural Tube Defect Repair DevicesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BayerDrospirenone/Ethinylestradiol/Methyltetrahydrofolate
Oregon TherapeuticsFetoscopic Neural Tube Defect Repair Devices
Human BioSciencesGenetics of Neural Tube Defects
Clinical Trials (3)
Total enrollment: 6,410 patients across 3 trials
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
Start: Apr 2007Est. completion: Sep 2008385 patients
Phase 3Completed
Fetoscopic Neural Tube Defect Repair
Start: Apr 2023Est. completion: Apr 203325 patients
N/ARecruiting
Genetics of Neural Tube Defects
Start: Apr 20096,000 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 6,410 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.